Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory data
Regulatory reports
Market reports
News analysis

Alerts LATEST ALERTS

  • Bulgaria Heated tobacco tax revenues for last three years revealed…
  • Switzerland Study reveals levels of heated tobacco use by 15-year-olds…
  • Egypt Senate passes bill that could place further restrictions on heated tobacco… ...
  • Philippines BIR and FDA issue clarifications and reminders about regulations…
  • Denmark Government looks to ban flavours in nicotine pouches…
  • Bulgaria Working group drafts amendment to ban nicotine pouch sales to under-18s…
  • Lithuania THC to be banned in tobacco products as of 1st April…
  • United Kingdom No evidence of young people moving from vape to tobacco…
  • Europe EC reveals environmental claims proposal…
  • United States FDA publishes list of tobacco-related petitions…
  • Cambodia Education minister tells schools to crack down on heated tobacco…
  • United Kingdom Ad breached the code by showing under-25s using heated tobacco…
View all
News analysis

Uncertainty hangs over PMI application as FDA misses its own deadline

Written by || 9th October 2017 || News analysis | Heated tobacco | North America United States

The US FDA has missed its own 180-day deadline for replying to the premarket tobacco application (PMTA) by Philip Morris International for its IQOS heated tobacco products ...

Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us

Related contents

PMI’s iQOS enters FDA process, edging closer to U.S. launch
American Vaping Association urges FDA to approve iQOS
PMTA and MRTP: navigating the path to FDA approval for reduced-risk products
© 2023
TobaccoIntelligence does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of TobaccoIntelligence,
does not accept any liability or responsibility for information or views published.